Anastasia N. Vasileva

Anastasia N. Vasileva

Auto-generated profile, based on publicly available information

Anastasia N. Vasileva

National Medical Research Center for Hematology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2023 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
OAOlga Aleshina
Olga Aleshina
KZKristina Zakurdaeva
Kristina Zakurdaeva
AVAnastasia N. Vasileva
Anastasia N. Vasileva
SDSergey K. Dubov
Sergey K. Dubov
VDVitaly S. Dubov
Vitaly S. Dubov
EPElena N. Parovichnikova
Elena N. Parovichnikova

Verified
Journal Article
Open access
PDF file
NRNatalya Risinskaya
Natalya Risinskaya
AAAbdulpatakh Abdulpatakhov
Abdulpatakh Abdulpatakhov
CYChabaeva Yulia
Chabaeva Yulia
OAOlga Aleshina
Olga Aleshina
MGMaria Gladysheva
Maria Gladysheva
EPElena Parovichnikova
Elena Parovichnikova
Tumor cells of acute lymphoblastic leukemia (ALL) may have various genetic abnormalities. Some of them lead to a complete loss of certain genes. Our aim was to reveal biallelic deletions of genes in Ph–negative T-ALL. Chromosomal microarray analysis (CMA) was performed for 47 patients with de novo Ph–negative T-ALL, who received treatment according to RALL-2016m clinical protocol at the National Medical Research Center for Hematology (Moscow, Russia) from 2017 to 2023. Out of forty-seven patients, only three had normal molecular karyotype. The other 44 patients had multiple gains, losses, and copy neutral losses of heterozygosity. Biallelic losses were found in 14 patients (30%). In ten patients (21%), a biallelic deletion of 9p21.3 involved a different number of genes, however CDKN2A gene loss was noted in all ten cases. For seven patients (15%), a biallelic deletion of 7q34 was found, including two genes—PRSS1, PRSS2 located within the T-cell receptor beta (TRB) locus. A clonal rearrangement of the TRB gene was revealed in 6 out of 7 cases with 7q34 biallelic loss. Both biallelic deletions can be considered favorable prognostic factors, with an association with 9p21 being statistically significant (p = 0.01) and a trend for 7q34 (p = 0.12) being observed.

28 December 2024 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
OAOlga Aleshina
Olga Aleshina
KAK. A. Akezheva
K. A. Akezheva
DED. Yu. Eroshenkov
D. Yu. Eroshenkov
AVA. N. Vasilyeva
A. N. Vasilyeva
ASA. E. Shchekina
A. E. Shchekina
EPE. N. Parovichnikova
E. N. Parovichnikova
Introduction. Patients with relapsed/refractory (r/r) Ph-positive acute lymphoblastic leukemia (ALL) have a poor prognosis and limited treatment options. New promising immunotherapies using CAR T cells or monoclonal antibodies (blinatumomab, inotuzumab/ozogamicin) in combination with tyrosine kinase inhibitors are being used for this group of patients. However, long-term results have not been studied when relapse or refractoriness develops after the use of one of these methods.Aim: to present a clinical observation of the use of anti-CD19 CAR T therapy after blinatumomab therapy in a patient with a relapsed course of Ph-positive acute lymphoblastic leukemia.Main findings. A 28-year-old patient was first diagnosed with Ph-positive B-ALL (transcript p210) in 2014. In the 1st line of treatment he was treated with therapy according to the protocol ‘ALL-2009’ with imatinib and allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, 2 months later the first molecular relapse was detected, and imatinib was replaced by dasatinib. In November 2016, a second relapse was diagnosed. In 2017, a third relapse with testicular involvement and T315I mutation was diagnosed, and therapy with ponatinib was initiated. In 2022, a 4th medullary relapse developed, and therapy with blinatumomab (5 courses) in combination with ponatinib was performed. After the 5th course of therapy, the appearance of leukaemides was noted, and asciminib was added to the therapy. However, no clinical effect was noted. The patient was treated with anti-CD19 CAR T therapy. A complete response to CAR T-cell therapy was confirmed on day 28 after CAR T administration. Further follow-up, over the course of one year, demonstrated stable clinical response and persistence of CD3-positive CAR T-cells. This case report of anti-CD19 CAR T cell therapy in a patient with CD19-positive combined relapse with massive extramedullary component after blinatumomab therapy demonstrated long-term efficacy with a 1-year follow-up.

25 October 2021 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
OAOlga Aleshina
Olga Aleshina
АВА. Н. Васильева
А. Н. Васильева
Introduction. The COVID-19 pandemic has led to the need to accelerate the development of vaccines targeting SARSCoV-2. A large number of researchers have already confi rmed that patients with cancer have a high risk of mortality from COVID-19. Hematologic diseases and the therapy of these diseases are very heterogeneous, therefore it is expected that the immune response to infection or vaccination will be more variable in this cohort of patients. Accordingly, questions arise regarding the safety and effi cacy of vaccines in the context of immune changes caused either by the hematological disease itself or by the therapy that is administered to the patient.Aim — to summarize the current understanding of the effi cacy and safety of vaccination against the SARS-CoV-2 in patients with hemoblastosis and other hematological diseases.Basic information. Legalized COVID-19 vaccines are safe and effective for the general population. Given the high mortality rate among patients with hematological diseases, which is ten times higher than the mortality rate in the general population, vaccination is a priority for this group of patients. The current lack of clinical trial data on the effectiveness and safety of vaccines against COVID-19 in hematological patients raises a large number of questions among specialists and patients. This is also due to the fact that for most of the approved vaccines immunocompromised patients were not included in the phase III clinical trials. Thus, most patients with hematological diseases could not participate in these studies, and therefore the effectiveness and safety of vaccines against the causative agent of COVID-19 have not been thoroughly studied in this group.Current recommendations for vaccination against COVID-19 in hematological patients are based on expert opinion, including past experience of immunizing these patients against other viral infections.Conclusions. Vaccination of patients with hematological diseases and their environment (medical staff, relatives, caregivers) is one of the necessary methods to prevent high mortality from a new coronavirus infection during the COVID-19 pandemic.

2 April 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
АВА. Н. Васильева
А. Н. Васильева
OAOlga Aleshina
Olga Aleshina
EKE. S. Kotova
E. S. Kotova
BBBella Biderman
Bella Biderman
TOTatiana Obukhova
Tatiana Obukhova
EPE. N. Parovichnikova
E. N. Parovichnikova
Background. Current chemotherapy protocols for T-cell acute lymphoblastic leukemia (T-ALL) allow achieving a 5-year overall survival of 60–90 %, but relapsed and refractory forms remain incurable situations.Aim. To determine the significance of immunophenotypic, cytogenetic and molecular markers in adult T-ALL patients receiving therapy according to the ALL-2016 protocol.Materials and methods. From December 2016 to June 2022, 113 patients with primary T-ALL were included in the study. Cytogenetic study was performed in 104 (92 %) patients; anomalies in the IKZF1 and NOTCH1 genes were investigated in 43 (38 %) patients.Results. The worst prognosis was in patients with ETP and near-ETP variants of T-ALL (3-year disease-free survival was 54 % in ETP group, 33 % in near-ETP group vs TI/II – 79 %, TIII – 89 %, TIV – 75 %). In early T-ALL variants, abnormal karyotype was most common (ETP – 80.7 %, near-ETP – 60 %). Aberrations in NOTCH1 gene were found in 53 % of cases (in 23 out of 43 patients), and no mutations were found in IKZF1 gene in our study. In the group with no NOTCH1 abnormalities, the overall survival was significantly worse than in the group with abnormalities (NOTCH1– – 52 % vs NOTCH1+ –81 %; p = 0.05).

14 June 2024 in MD-Onco
Verified
Journal Article
Open access
PDF file
KAK. A. Akezheva
K. A. Akezheva
OAOlga Aleshina
Olga Aleshina
АВА. Н. Васильева
А. Н. Васильева
VDV. N. Dvirnyk
V. N. Dvirnyk
AEA. A. Ershov
A. A. Ershov
VTV. V. Troitskaya
V. V. Troitskaya
Acute promyelocytic leukemia (APL) is a blood tumor characterized by aggressive clinical progression with characteristic clinical and laboratory signs (typical tumor cell morphology, severe hemorrhagic syndrome, hemorrhages with hematoma formation, excessive fibrinolysis, disseminated intravascular coagulation syndrome) but modern approaches to therapy potentially make this disease fully curable. APL is considered one of the most studied subtypes of acute leukemia and is characterized by abnormal proliferation of promyelocytes in the bone marrow. The morphologic picture of APL is quite diverse, but an increased basophil count represents a rare manifestation that requires further study and understanding of its significance. Currently, there are limited scientific data on the clinical course and response to standard therapy in patients with APL presenting with basophilia.